Characteristics of Interim Publications of Randomized Clinical Trials and Comparison With Final Publications

被引：14
作者：
Woloshin, Steven [1 ]
Schwartz, Lisa M. [1 ]
Bagley, Pamela J. [2 ]
Blunt, Heather B. [2 ]
White, Brian [3 ]
机构：
[1] Dartmouth Inst Hlth Policy & Clin Practice, Ctr Med Media, Lebanon, NH USA
[2] Dartmouth Coll, Biomed Lib, Hanover, NH 03755 USA
[3] Atlanticare Reg Med Ctr, Pomona, NJ USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2018年 / 319卷 / 04期
基金：
美国医疗保健研究与质量局;
关键词：
D O I：
10.1001/jama.2017.20653
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：404 / 406
页数：3
相关论文
共 6 条
[1]   Stopping Randomized Trials Early for Benefit and Estimation of Treatment Effects Systematic Review and Meta-regression Analysis [J].
Bassler, Dirk ;
Briel, Matthias ;
Montori, Victor M. ;
Lane, Melanie ;
Glasziou, Paul ;
Zhou, Qi ;
Heels-Ansdell, Diane ;
Walter, Stephen D. ;
Guyatt, Gordon H. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (12) :1180-1187
[2]   Publishing interim results of randomised clinical trials in peer-reviewed journals [J].
Counsell, Nicholas ;
Biri, Despina ;
Fraczek, Joanna ;
Hackshaw, Allan .
CLINICAL TRIALS, 2017, 14 (01) :67-77
[3]   High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients - final analysis of a randomized, multicenter, phase III trial [J].
Petzer, Andreas L. ;
Fong, Dominic ;
Lion, Thomas ;
Dyagil, Irina ;
Masliak, Zvenyslava ;
Bogdanovic, Andrija ;
Griskevicius, Laimonas ;
Lejniece, Sandra ;
Goranov, Stefan ;
Gercheva, Liana ;
Stojanovic, Aleksandar ;
Peytchev, Dontcho ;
Tzvetkov, Nikolay ;
Griniute, Rasa ;
Stanchev, Atanas ;
Grubinger, Thomas ;
Kwakkelstein, Marthin ;
Schuld, Peter ;
Gastl, Guenther ;
Wolf, Dominik .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (10) :1562-1569
[4]   High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study [J].
Petzer, Andreas L. ;
Wolf, Dominik ;
Fong, Dominic ;
Lion, Thomas ;
Dyagil, Irina ;
Masliak, Zvenyslava ;
Bogdanovic, Andrija ;
Griskevicius, Laimonas ;
Lejniece, Sandra ;
Goranov, Stefan ;
Gercheva, Liana ;
Stojanovic, Aleksandar ;
Peytchev, Dontcho ;
Tzvetkov, Nikolay ;
Griniute, Rasa ;
Oucheva, Radka ;
Ulmer, Hanno ;
Kwakkelstein, Marthin ;
Rancati, Francesca ;
Gastl, Guenther .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (06) :908-913
[5]   Interim results in clinical trials: Do we need to keep all interim randomised clinical trial results confidential? [J].
Stephens, R. J. ;
Langley, R. E. ;
Mulvenna, P. ;
Nankivell, M. ;
Vail, A. ;
Parmar, M. K. B. .
LUNG CANCER, 2014, 85 (02) :116-118
[6]   Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research [J].
Wang, Hao ;
Rosner, Gary L. ;
Goodman, Steven N. .
CLINICAL TRIALS, 2016, 13 (06) :621-631
1